Venmax Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹5.28 crore and net profit of ₹0.12 crore for the September 2026 quarter.
Venmax Drugs (BSE: VENMAX) closed at ₹12.20 on 20 Nov 2026, down 58.4% over the past year. Its market capitalisation is ₹18 crore and it trades at 46.5 times earnings.
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.